Addex Net Working Capital vs Total Assets Analysis
ADXN Stock | USD 8.15 0.62 8.23% |
Addex Therapeutics financial indicator trend analysis is way more than just evaluating Addex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Addex Therapeutics is a good investment. Please check the relationship between Addex Therapeutics Net Working Capital and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
Net Working Capital vs Total Assets
Net Working Capital vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Addex Therapeutics Net Working Capital account and Total Assets. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Addex Therapeutics' Net Working Capital and Total Assets is 0.52. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Total Assets in the same time period over historical financial statements of Addex Therapeutics, assuming nothing else is changed. The correlation between historical values of Addex Therapeutics' Net Working Capital and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Addex Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Working Capital i.e., Addex Therapeutics' Net Working Capital and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.52 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Working Capital
Total Assets
Total assets refers to the total amount of Addex Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Addex Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from Addex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Addex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.At this time, Addex Therapeutics' Enterprise Value Over EBITDA is very stable compared to the past year. As of the 9th of December 2024, Enterprise Value Multiple is likely to grow to 0.01, while Selling General Administrative is likely to drop about 4.7 M.
Addex Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Addex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Addex Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 33.0M | 20.2M | 22.5M | 8.3M | 4.6M | 4.4M | |
Other Current Liab | 2.0M | 1.3M | 1.9M | 1.6M | 1.2M | 1.2M | |
Total Current Liabilities | 5.7M | 3.6M | 4.1M | 3.3M | 2.9M | 4.0M | |
Total Stockholder Equity | 25.5M | 14.6M | 16.9M | 4.9M | 1.1M | 1.1M | |
Property Plant And Equipment Net | 571.0K | 633.1K | 542.1K | 398.7K | 352.9K | 335.3K | |
Current Deferred Revenue | 212.7K | 1.1M | 820.1K | 235.0K | 270.2K | 412.9K | |
Net Debt | (31.0M) | (18.1M) | (20.0M) | (6.6M) | (3.5M) | (3.7M) | |
Retained Earnings | (300.8M) | (313.7M) | (329.1M) | (349.9M) | (360.4M) | (378.4M) | |
Accounts Payable | 2.2M | 983.5K | 1.8M | 1.3M | 984.4K | 913.8K | |
Cash | 31.5M | 18.7M | 20.5M | 7.0M | 3.9M | 3.7M | |
Non Current Assets Total | 639.9K | 692.2K | 600.0K | 453.1K | 407.3K | 386.9K | |
Non Currrent Assets Other | 68.9K | 59.1K | 57.9K | 54.4K | 54.3K | 51.6K | |
Cash And Short Term Investments | 31.6M | 18.8M | 20.5M | 7.0M | 3.9M | 3.7M | |
Common Stock Shares Outstanding | 26.4M | 26.7M | 34.1M | 45.2M | 74.3M | 78.0M | |
Liabilities And Stockholders Equity | 33.0M | 20.2M | 22.5M | 8.3M | 4.6M | 4.4M | |
Other Current Assets | 734.0K | 661.2K | 1.1M | 270.4K | 217.0K | 206.2K | |
Other Stockholder Equity | 286.4M | 280.8M | 272.3M | 327.9M | 329.9M | 288.2M | |
Total Liab | 7.5M | 5.6M | 5.6M | 3.4M | 3.5M | 4.5M | |
Property Plant And Equipment Gross | 571.0K | 633.1K | 4.3M | 4.4M | 4.7M | 2.4M | |
Total Current Assets | 32.4M | 19.5M | 21.9M | 7.8M | 4.2M | 4.0M | |
Short Term Debt | 373.0K | 308.6K | 287.7K | 286.1K | 274.0K | 193.4K | |
Non Current Liabilities Total | 1.8M | 2.0M | 1.5M | 87.0K | 603.1K | 761.6K | |
Accumulated Other Comprehensive Income | 7.1M | 8.6M | 24.4M | 25.8M | 29.8M | 31.3M | |
Net Receivables | 118.0K | 68.4K | 324.4K | 598.3K | 151.3K | 271.7K | |
Other Liab | 639.4K | 1.6M | 1.7M | 1.3M | 1.5M | 813.2K | |
Net Tangible Assets | 25.5M | 14.6M | 16.9M | 4.9M | 5.6M | 5.4M | |
Other Assets | 68.9K | 59.1K | 57.9K | 54.4K | 48.9K | 66.0K | |
Short Term Investments | 14.0K | 64.9K | 17.1K | 3.2K | 848.0 | 805.6 | |
Property Plant Equipment | 571.0K | 633.1K | 542.1K | 398.7K | 458.5K | 275.1K | |
Net Invested Capital | 25.5M | 14.6M | 16.9M | 4.9M | 1.1M | 1.1M | |
Net Working Capital | 26.7M | 15.9M | 17.8M | 4.5M | 1.3M | 1.3M |
Pair Trading with Addex Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Addex Stock
0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.63 | LLY | Eli Lilly | PairCorr |
0.73 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
Moving against Addex Stock
0.76 | GLABF | Gemina Laboratories | PairCorr |
0.69 | LFCR | Lifecore Biomedical | PairCorr |
0.63 | BMY | Bristol Myers Squibb | PairCorr |
0.49 | KMDA | Kamada | PairCorr |
0.36 | CTLT | Catalent | PairCorr |
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Addex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (21.86) | Revenue Per Share 1.2 | Quarterly Revenue Growth (0.82) | Return On Assets (0.62) | Return On Equity (1.26) |
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.